Toward a Radically Simple Multi‐Modal Nasal Spray for Preventing Respiratory Infections
Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowin...
Saved in:
Published in | Advanced materials (Weinheim) Vol. 36; no. 46; pp. e2406348 - n/a |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley Subscription Services, Inc
01.11.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi‐modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi‐modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre‐exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily‐use prophylactic against respiratory infections.
A pathogen capture and neutralizing spray (PCANS) is reported to prevent respiratory infections through a multi‐modal approach. PCANS coats the nasal cavity, capturing large respiratory droplets and serving as a physical barrier against viruses and bacteria, while neutralizing them with over 99.99% effectiveness. In mice, PCANS shows nasal retention for ≈8 hours and offers pre‐exposure protection against lethal viral infections. |
---|---|
AbstractList | Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi‐modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi‐modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre‐exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily‐use prophylactic against respiratory infections. Nasal sprays for pre-exposure prophylaxis against respiratory infections show limited protection (20-70%), largely due to their single mechanism of action-either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi-modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi-modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre-exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily-use prophylactic against respiratory infections.Nasal sprays for pre-exposure prophylaxis against respiratory infections show limited protection (20-70%), largely due to their single mechanism of action-either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi-modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi-modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre-exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily-use prophylactic against respiratory infections. Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi‐modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi‐modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre‐exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily‐use prophylactic against respiratory infections. A pathogen capture and neutralizing spray (PCANS) is reported to prevent respiratory infections through a multi‐modal approach. PCANS coats the nasal cavity, capturing large respiratory droplets and serving as a physical barrier against viruses and bacteria, while neutralizing them with over 99.99% effectiveness. In mice, PCANS shows nasal retention for ≈8 hours and offers pre‐exposure protection against lethal viral infections. |
Author | Agus, Eli Kaur, Shahdeep Mwangi, John Joseph, John Mebratu, Yohannes A Joshi, Nitin Karp, Jeffrey M Baby, Helna Mary Yu, Anthony Li, Xiang‐Ling Swain, Kabir Snapper, Olivia Bhatia, Eshant Ranganathan, Sruthi Tesfaigzi, Yohannes Quintero, Joselyn Rojas Nair, Remya Kenney, Devin Gao, Jingjing Lee, Dongtak Park, Dongsung Douam, Florian Kage, Julian Luo, James N Shah, Purna |
Author_xml | – sequence: 1 givenname: John surname: Joseph fullname: Joseph, John organization: Harvard Medical School – sequence: 2 givenname: Helna Mary surname: Baby fullname: Baby, Helna Mary organization: Brigham and Women's Hospital – sequence: 3 givenname: Joselyn Rojas surname: Quintero fullname: Quintero, Joselyn Rojas organization: Brigham and Women's Hospital – sequence: 4 givenname: Devin surname: Kenney fullname: Kenney, Devin organization: Chobanian & Avedisian School of Medicine – sequence: 5 givenname: Yohannes A surname: Mebratu fullname: Mebratu, Yohannes A organization: Brigham and Women's Hospital – sequence: 6 givenname: Eshant surname: Bhatia fullname: Bhatia, Eshant organization: Indian Institute of Technology – sequence: 7 givenname: Purna surname: Shah fullname: Shah, Purna organization: Brigham and Women's Hospital – sequence: 8 givenname: Kabir surname: Swain fullname: Swain, Kabir organization: Brigham and Women's Hospital – sequence: 9 givenname: Dongtak surname: Lee fullname: Lee, Dongtak organization: Harvard Medical School – sequence: 10 givenname: Shahdeep surname: Kaur fullname: Kaur, Shahdeep organization: Harvard Medical School – sequence: 11 givenname: Xiang‐Ling surname: Li fullname: Li, Xiang‐Ling organization: Brigham and Women's Hospital – sequence: 12 givenname: John surname: Mwangi fullname: Mwangi, John organization: Brigham and Women's Hospital – sequence: 13 givenname: Olivia surname: Snapper fullname: Snapper, Olivia organization: Brigham and Women's Hospital – sequence: 14 givenname: Remya surname: Nair fullname: Nair, Remya organization: Harvard Medical School – sequence: 15 givenname: Eli surname: Agus fullname: Agus, Eli organization: Brigham and Women's Hospital – sequence: 16 givenname: Sruthi surname: Ranganathan fullname: Ranganathan, Sruthi organization: Brigham and Women's Hospital – sequence: 17 givenname: Julian surname: Kage fullname: Kage, Julian organization: Brigham and Women's Hospital – sequence: 18 givenname: Jingjing surname: Gao fullname: Gao, Jingjing organization: Harvard Medical School – sequence: 19 givenname: James N surname: Luo fullname: Luo, James N organization: Brigham and Women's Hospital – sequence: 20 givenname: Anthony surname: Yu fullname: Yu, Anthony organization: Harvard Medical School – sequence: 21 givenname: Dongsung surname: Park fullname: Park, Dongsung organization: Brookhaven National Laboratory – sequence: 22 givenname: Florian surname: Douam fullname: Douam, Florian organization: Chobanian & Avedisian School of Medicine – sequence: 23 givenname: Yohannes surname: Tesfaigzi fullname: Tesfaigzi, Yohannes email: ytesfaigzi@bwh.harvard.edu organization: Brigham and Women's Hospital – sequence: 24 givenname: Jeffrey M surname: Karp fullname: Karp, Jeffrey M email: jmkarp@bwh.harvard.edu organization: Harvard Stem Cell Institute – sequence: 25 givenname: Nitin orcidid: 0000-0001-8138-7611 surname: Joshi fullname: Joshi, Nitin email: njoshi@bwh.harvard.edu organization: Harvard Medical School |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39318086$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0btuFDEUBmALBZFNoKVEI9HQzMa3GdvlKuESKUtQEgqq0YkvyJFnPNgzRNPxCDwjT4KjTYJEk8Yu_P3W0fkP0N4QB4vQa4LXBGN6BKaHNcWU45Zx-QytSENJzbFq9tAKK9bUquVyHx3kfIMxVi1uX6B9phiRWLYr9O0q3kIyFVQXYLyGEJbq0vdjsNV2DpP_8-v3NhoI1WfI5bwcEyyVi6n6kuxPO0x--F5d2Dz6BFNMS3U6OKsnH4f8Ej13ELJ9dX8foq8f3l8df6rPzj-eHm_Oas2olLVjTAvBgDRYUq6Eo9emEdwp0EYIxQwBqp0GbLTSoFvnOFWCNYIIW94EO0Tvdv-OKf6YbZ663mdtQ4DBxjl3jGDFKZEEF_r2P3oT5zSU6YqikpcRMC3qzb2ar3trujH5HtLSPSytgPUO6BRzTtY9EoK7u1a6u1a6x1ZKQO0Ctz7Y5QndbU62m3_ZvzL3kEo |
Cites_doi | 10.3109/10717544.2013.849778 10.1038/s41591-021-01301-0 10.1172/JCI148517 10.1371/journal.pone.0237480 10.1002/med.21941 10.3390/polym12020329 10.1136/bmjopen-2021-059661 10.1002/advs.202003895 10.1134/S207997802003005X 10.1038/s41586-021-04389-z 10.1038/s41421-022-00510-2 10.1016/j.ijpharm.2010.09.028 10.1016/B978-0-8155-2025-2.10010-1 10.1038/s41591-020-0868-6 10.3389/fmedt.2021.687681 10.1038/s41579-018-0001-8 10.1080/03639040802149046 10.1016/j.jcv.2022.105248 10.1038/s41563-023-01475-7 10.1371/journal.pone.0014320 10.1016/j.celrep.2020.108062 10.1002/adma.202008304 10.3390/pharmaceutics14030530 10.1016/j.supflu.2022.105762 10.1038/s41598-021-99765-0 10.1371/journal.ppat.1008098 10.1371/journal.ppat.1004089 10.1084/jem.89.1.11 10.3934/biophy.2021008 10.1111/j.2042-7158.1987.tb03142.x 10.1186/s12890-020-01187-7 10.3390/ijms241512132 10.1371/journal.pone.0040422 10.1093/cid/ciac448 10.1081/DDC-100101325 10.1007/978-1-4939-6591-5_2 10.2147/IJGM.S328486 10.1016/j.cell.2020.05.042 10.1248/bpb.b14-00398 10.1080/14760584.2021.1915140 10.1111/j.2042-7158.1996.tb03929.x 10.3390/ijms222413202 10.1073/pnas.2202069119 10.1002/jbm.a.34851 10.1128/JVI.00159-10 10.1016/j.otohns.2003.07.005 10.1016/j.virol.2015.02.041 10.3390/immuno2040036 10.1001/jama.2020.8946 10.1016/j.lansea.2022.100036 10.1371/journal.pone.0021207 10.1016/S1473-3099(22)00320-6 10.1001/jamaoto.2020.3053 10.1056/NEJMoa2107058 10.1186/s12989-020-0339-8 10.1002/lary.29935 10.1002/EXP.20210038 10.1126/sciimmunol.abl9929 10.1007/978-1-4614-7978-9_5 10.1001/jamanetworkopen.2022.6108 10.1152/ajplung.00552.2020 10.1038/s43246-021-00153-y 10.1016/j.cegh.2021.100826 10.4168/aair.2019.11.3.306 10.1038/s41586-021-03673-2 10.1016/j.carres.2014.02.018 10.3389/fbioe.2020.581995 10.1021/acs.jpcc.7b03885 10.1513/AnnalsATS.201311-405PS 10.1016/j.xphs.2015.12.016 10.1016/j.apm.2022.08.008 10.1016/j.ejpb.2007.01.010 10.1002/viw2.16 10.1016/j.resp.2008.05.018 10.1038/ni1001-907 |
ContentType | Journal Article |
Copyright | 2024 Wiley‐VCH GmbH 2024 Wiley‐VCH GmbH. |
Copyright_xml | – notice: 2024 Wiley‐VCH GmbH – notice: 2024 Wiley‐VCH GmbH. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7SR 8BQ 8FD JG9 7X8 |
DOI | 10.1002/adma.202406348 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Engineered Materials Abstracts METADEX Technology Research Database Materials Research Database MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Materials Research Database Engineered Materials Abstracts Technology Research Database METADEX MEDLINE - Academic |
DatabaseTitleList | Materials Research Database CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1521-4095 |
EndPage | n/a |
ExternalDocumentID | 39318086 10_1002_adma_202406348 ADMA202406348 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital – fundername: Fulbright Nehru Postdoctoral Fellowship – fundername: Gillian Reny Stepping Strong Center for Trauma Innovation at the Brigham and Women's Hospital – fundername: Boston University – fundername: Peter Paul Career Development Award – fundername: NIAID NIH HHS grantid: R01 AI148180 |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 23M 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANLZ AAONW AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABPVW ACAHQ ACCFJ ACCZN ACGFS ACIWK ACPOU ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM EBS F00 F01 F04 F5P G-S G.N GNP GODZA H.T H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D Q.N Q11 QB0 QRW R.K RNS ROL RWI RWM RX1 RYL SUPJJ TN5 UB1 UPT V2E W8V W99 WBKPD WFSAM WIB WIH WIK WJL WOHZO WQJ WRC WXSBR WYISQ XG1 XPP XV2 YR2 ZZTAW ~02 ~IA ~WT .Y3 31~ 6TJ 8WZ A6W AANHP AASGY AAYOK AAYXX ABEML ACBWZ ACRPL ACSCC ACYXJ ADMLS ADNMO AETEA AEYWJ AFFNX AGHNM AGQPQ AGYGG ASPBG AVWKF AZFZN CITATION EJD FEDTE FOJGT HF~ HVGLF LW6 M6K NDZJH PALCI RIWAO RJQFR SAMSI WTY ZY4 AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7SR 8BQ 8FD JG9 7X8 |
ID | FETCH-LOGICAL-c3288-f33c773a15082497f2bd574f9acd7793d1a2cfca0dc9cac6ff429735717ed1a73 |
IEDL.DBID | DR2 |
ISSN | 0935-9648 1521-4095 |
IngestDate | Thu Jul 10 18:32:27 EDT 2025 Sat Jul 26 00:07:30 EDT 2025 Mon Jul 21 06:02:07 EDT 2025 Tue Jul 01 00:54:56 EDT 2025 Wed Jan 22 17:14:58 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 46 |
Keywords | pathogen capture virus neutralization broad spectrum protection nasal spray antiviral nasal prophylaxis antibacterial respiratory infections |
Language | English |
License | 2024 Wiley‐VCH GmbH. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3288-f33c773a15082497f2bd574f9acd7793d1a2cfca0dc9cac6ff429735717ed1a73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-8138-7611 |
PMID | 39318086 |
PQID | 3128450802 |
PQPubID | 2045203 |
PageCount | 20 |
ParticipantIDs | proquest_miscellaneous_3109421810 proquest_journals_3128450802 pubmed_primary_39318086 crossref_primary_10_1002_adma_202406348 wiley_primary_10_1002_adma_202406348_ADMA202406348 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-11-01 |
PublicationDateYYYYMMDD | 2024-11-01 |
PublicationDate_xml | – month: 11 year: 2024 text: 2024-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Weinheim |
PublicationTitle | Advanced materials (Weinheim) |
PublicationTitleAlternate | Adv Mater |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2023; 76 2021; 27 2022; 132 2021; 20 2015; 38 2021; 22 2020; 20 2019; 11 2023; 9 2019; 15 2020; 17 2008; 34 2016; 105 2020; 12 2020; 323 2021; 320 2020; 11 2022; 22 2020; 10 2013; 6 1987; 39 2014; 21 2020; 8 2023; 24 2023; 22 2021; 33 2020; 1 2004; 130 2021; 595 2017; 121 2010; 5 2022; 602 2007; 67 2014; 11 2014; 10 2022; 155 2021; 8 2022; 112 2015; 481 2021; 3 2021; 2 2022; 191 2012 2017; 1522 2000; 26 2010; 402 2010 2020; 182 2020; 146 2021; 385 2020; 32 2022; 119 2011; 6 2008; 163 2010; 84 2021; 14 2023; 43 1990; 2 2021; 16 1949; 89 2021; 12 2021; 11 2022; 3 2022 2022; 5 2020 2022; 7 2022; 12 2020; 26 2022; 14 2021; 373 2021; 131 2001; 2 2022; 2 2012; 7 1996; 48 2018; 16 2014; 388 2014; 102 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_69_1 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_42_1 e_1_2_10_40_1 e_1_2_10_70_1 e_1_2_10_2_1 e_1_2_10_72_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_74_1 e_1_2_10_53_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_55_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_57_1 e_1_2_10_78_1 e_1_2_10_58_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_32_1 Wang C. C. (e_1_2_10_8_1) 2021; 373 e_1_2_10_30_1 e_1_2_10_51_1 Gizurarson S. (e_1_2_10_76_1) 1990; 2 Cannon M. L. (e_1_2_10_66_1) 2020 e_1_2_10_82_1 e_1_2_10_61_1 Xie X. (e_1_2_10_80_1) 2020; 11 e_1_2_10_84_1 e_1_2_10_29_1 e_1_2_10_63_1 Gaffar A. (e_1_2_10_26_1) 2022 e_1_2_10_65_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_67_1 e_1_2_10_24_1 e_1_2_10_45_1 e_1_2_10_22_1 e_1_2_10_43_1 e_1_2_10_20_1 Go C. C. (e_1_2_10_27_1) 2020 e_1_2_10_41_1 e_1_2_10_71_1 e_1_2_10_1_1 e_1_2_10_73_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_75_1 e_1_2_10_54_1 Djupesland P. G. (e_1_2_10_56_1) 2020 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_38_1 e_1_2_10_77_1 e_1_2_10_79_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 Rowe R. C. (e_1_2_10_49_1) 2012 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_31_1 e_1_2_10_50_1 Kulkarni V. (e_1_2_10_59_1) 2012 e_1_2_10_60_1 e_1_2_10_81_1 e_1_2_10_62_1 e_1_2_10_83_1 e_1_2_10_64_1 e_1_2_10_28_1 e_1_2_10_47_1 e_1_2_10_68_1 |
References_xml | – volume: 112 start-page: 649 year: 2022 publication-title: Appl. Math. Model. – volume: 24 year: 2023 publication-title: Int. J. Mol. Sci. – start-page: 247 year: 2010 end-page: 290 – volume: 373 start-page: 1979 year: 2021 publication-title: Science – volume: 22 year: 2021 publication-title: Int. J. Mol. Sci. – volume: 12 year: 2020 publication-title: Polymers (Basel) – volume: 15 year: 2019 publication-title: PLoS Pathog. – volume: 595 start-page: 718 year: 2021 publication-title: Nature – volume: 102 start-page: 1788 year: 2014 publication-title: J. Biomed. Mater. Res A – volume: 7 year: 2012 publication-title: PLoS One – volume: 182 start-page: 429 year: 2020 publication-title: Cell – volume: 121 year: 2017 publication-title: J. Phys. Chem. C – volume: 5 year: 2022 publication-title: JAMA Netw. Open – volume: 10 year: 2014 publication-title: PLoS Pathog. – volume: 3 year: 2021 publication-title: Front Med Technol – volume: 11 start-page: 404 year: 2014 publication-title: Ann. Am. Thorac. Soc. – volume: 14 start-page: 530 year: 2022 publication-title: Pharmaceutics – volume: 10 start-page: 140 year: 2020 publication-title: Reviews and Advances in Chemistry – volume: 402 start-page: 89 year: 2010 publication-title: Int. J. Pharm. – volume: 2 year: 2021 publication-title: Commun Mater – volume: 105 start-page: 1209 year: 2016 publication-title: J. Pharm. Sci. – volume: 48 start-page: 1237 year: 1996 publication-title: J. Pharm. Pharmacol. – start-page: 485 year: 2020 end-page: 495 – volume: 22 start-page: 1293 year: 2022 publication-title: Lancet Infect. Dis. – volume: 20 year: 2020 publication-title: BMC Pulm Med – volume: 33 year: 2021 publication-title: Adv. Mater. – volume: 2 start-page: 105 year: 1990 publication-title: Acta Pharm. Nord. – volume: 1 year: 2020 publication-title: VIEW – volume: 2 start-page: 571 year: 2022 publication-title: Immuno – volume: 9 start-page: 2 year: 2023 publication-title: Cell Discov. – volume: 14 start-page: 6277 year: 2021 publication-title: Int. J. Gen. Med. – volume: 130 start-page: 131 year: 2004 publication-title: Otolaryngol. – Head Neck Surg. – volume: 11 year: 2020 publication-title: Nat. Commun. – volume: 34 start-page: 923 year: 2008 publication-title: Drug Dev. Ind. Pharm. – volume: 89 start-page: 11 year: 1949 publication-title: J. Exp. Med. – volume: 16 year: 2021 publication-title: PLoS One – volume: 43 start-page: 932 year: 2023 publication-title: Med. Res. Rev. – volume: 8 year: 2021 publication-title: Adv. Sci. – volume: 21 start-page: 62 year: 2014 publication-title: Drug Deliv – volume: 155 year: 2022 publication-title: Journal of Clinical Virology – volume: 388 start-page: 125 year: 2014 publication-title: Carbohydr. Res. – volume: 38 start-page: 497 year: 2015 publication-title: Biol. Pharm. Bull – volume: 5 year: 2010 publication-title: PLoS One – volume: 131 year: 2021 publication-title: J. Clin. Invest. – volume: 320 start-page: L750 year: 2021 publication-title: Am. J .Physiol. Lung Cell Mol. Physiol. – volume: 602 start-page: 671 year: 2022 publication-title: Nature – volume: 20 start-page: 635 year: 2021 publication-title: Expert Rev. Vaccines – volume: 8 start-page: 111 year: 2021 publication-title: AIMS Biophys. – volume: 6 start-page: 99 year: 2013 publication-title: Sterile Product Development – volume: 2 start-page: 907 year: 2001 publication-title: Nat. Immunol. – volume: 17 start-page: 5 year: 2020 publication-title: Part. Fibre Toxicol. – volume: 11 year: 2021 publication-title: Sci. Rep. – volume: 26 start-page: 681 year: 2020 publication-title: Nat. Med. – volume: 16 start-page: 355 year: 2018 publication-title: Nat. Rev. Microbiol. – volume: 39 start-page: 966 year: 1987 publication-title: J. Pharm. Pharmacol. – volume: 2 year: 2022 publication-title: Exploration – volume: 12 year: 2021 publication-title: Clin. Epidemiol. Glob. Health – volume: 11 start-page: 306 year: 2019 publication-title: Allergy Asthma Immunol. Res. – volume: 26 start-page: 975 year: 2000 publication-title: Drug Dev. Ind. Pharm. – volume: 27 start-page: 591 year: 2021 publication-title: Nat. Med. – volume: 22 start-page: 903 year: 2023 publication-title: Nat. Mater. – volume: 385 start-page: 320 year: 2021 publication-title: N. Engl. J. Med. – year: 2020 publication-title: Cureus – volume: 191 year: 2022 publication-title: J. Supercrit. Fluids – volume: 12 year: 2022 publication-title: BMJ Open – year: 2012 – volume: 8 year: 2020 publication-title: Front. Bioeng. Biotechnol. – year: 2022 publication-title: Preprint, Research Square – volume: 119 year: 2022 publication-title: Proc Natl Acad Sci U S A – year: 2020 publication-title: bioRxiv preprint – volume: 84 start-page: 8607 year: 2010 publication-title: J. Virol. – volume: 1522 start-page: 17 year: 2017 publication-title: Methods Mol. Biol. – volume: 481 start-page: 107 year: 2015 publication-title: Virology – volume: 146 start-page: 1054 year: 2020 publication-title: JAMA Otolaryngol. Head Neck Surg. – volume: 3 year: 2022 publication-title: Lancet Region. Health – Southeast Asia – volume: 6 year: 2011 publication-title: PLoS One – year: 2012 publication-title: Formulat. Characteriz. Nasal Sprays – volume: 323 start-page: 2386 year: 2020 publication-title: JAMA – J. Am. Med. Assoc. – volume: 32 year: 2020 publication-title: Cell Rep. – volume: 67 start-page: 132 year: 2007 publication-title: Eur. J. Pharm. Biopharm. – volume: 76 year: 2023 publication-title: Clin. Infect. Dis. – volume: 163 start-page: 244 year: 2008 publication-title: Respir. Physiol. Neurobiol. – volume: 132 start-page: 2089 year: 2022 publication-title: Laryngoscope – volume: 7 year: 2022 publication-title: Sci Immunol – ident: e_1_2_10_78_1 doi: 10.3109/10717544.2013.849778 – ident: e_1_2_10_3_1 doi: 10.1038/s41591-021-01301-0 – year: 2012 ident: e_1_2_10_59_1 publication-title: Formulat. Characteriz. Nasal Sprays – ident: e_1_2_10_9_1 doi: 10.1172/JCI148517 – ident: e_1_2_10_18_1 doi: 10.1371/journal.pone.0237480 – ident: e_1_2_10_64_1 doi: 10.1002/med.21941 – ident: e_1_2_10_38_1 doi: 10.3390/polym12020329 – ident: e_1_2_10_17_1 doi: 10.1136/bmjopen-2021-059661 – year: 2020 ident: e_1_2_10_66_1 publication-title: bioRxiv preprint – ident: e_1_2_10_29_1 doi: 10.1002/advs.202003895 – year: 2020 ident: e_1_2_10_27_1 publication-title: Cureus – ident: e_1_2_10_67_1 doi: 10.1134/S207997802003005X – ident: e_1_2_10_65_1 doi: 10.1038/s41586-021-04389-z – ident: e_1_2_10_13_1 doi: 10.1038/s41421-022-00510-2 – ident: e_1_2_10_81_1 doi: 10.1016/j.ijpharm.2010.09.028 – volume: 373 start-page: 1979 year: 2021 ident: e_1_2_10_8_1 publication-title: Science – ident: e_1_2_10_83_1 doi: 10.1016/B978-0-8155-2025-2.10010-1 – ident: e_1_2_10_10_1 doi: 10.1038/s41591-020-0868-6 – ident: e_1_2_10_40_1 doi: 10.3389/fmedt.2021.687681 – ident: e_1_2_10_15_1 doi: 10.1038/s41579-018-0001-8 – ident: e_1_2_10_31_1 doi: 10.1080/03639040802149046 – ident: e_1_2_10_23_1 doi: 10.1016/j.jcv.2022.105248 – ident: e_1_2_10_77_1 doi: 10.1038/s41563-023-01475-7 – ident: e_1_2_10_21_1 doi: 10.1371/journal.pone.0014320 – ident: e_1_2_10_62_1 doi: 10.1016/j.celrep.2020.108062 – ident: e_1_2_10_28_1 doi: 10.1002/adma.202008304 – ident: e_1_2_10_16_1 doi: 10.3390/pharmaceutics14030530 – ident: e_1_2_10_36_1 doi: 10.1016/j.supflu.2022.105762 – ident: e_1_2_10_63_1 doi: 10.1038/s41598-021-99765-0 – ident: e_1_2_10_61_1 doi: 10.1371/journal.ppat.1008098 – ident: e_1_2_10_14_1 doi: 10.1371/journal.ppat.1004089 – ident: e_1_2_10_42_1 doi: 10.1084/jem.89.1.11 – ident: e_1_2_10_45_1 doi: 10.3934/biophy.2021008 – ident: e_1_2_10_52_1 doi: 10.1111/j.2042-7158.1987.tb03142.x – ident: e_1_2_10_84_1 doi: 10.1186/s12890-020-01187-7 – ident: e_1_2_10_50_1 doi: 10.3390/ijms241512132 – ident: e_1_2_10_44_1 doi: 10.1371/journal.pone.0040422 – ident: e_1_2_10_22_1 doi: 10.1093/cid/ciac448 – ident: e_1_2_10_32_1 doi: 10.1081/DDC-100101325 – ident: e_1_2_10_82_1 doi: 10.1007/978-1-4939-6591-5_2 – ident: e_1_2_10_46_1 doi: 10.2147/IJGM.S328486 – ident: e_1_2_10_12_1 doi: 10.1016/j.cell.2020.05.042 – volume: 2 start-page: 105 year: 1990 ident: e_1_2_10_76_1 publication-title: Acta Pharm. Nord. – ident: e_1_2_10_57_1 doi: 10.1248/bpb.b14-00398 – ident: e_1_2_10_2_1 doi: 10.1080/14760584.2021.1915140 – ident: e_1_2_10_48_1 doi: 10.1111/j.2042-7158.1996.tb03929.x – ident: e_1_2_10_25_1 doi: 10.3390/ijms222413202 – ident: e_1_2_10_72_1 doi: 10.1073/pnas.2202069119 – ident: e_1_2_10_79_1 doi: 10.1002/jbm.a.34851 – ident: e_1_2_10_73_1 doi: 10.1128/JVI.00159-10 – volume-title: Handbook of Pharmaceutical Excipients year: 2012 ident: e_1_2_10_49_1 – ident: e_1_2_10_55_1 doi: 10.1016/j.otohns.2003.07.005 – ident: e_1_2_10_74_1 doi: 10.1016/j.virol.2015.02.041 – start-page: 485 volume-title: Ther Deliv year: 2020 ident: e_1_2_10_56_1 – ident: e_1_2_10_6_1 doi: 10.3390/immuno2040036 – ident: e_1_2_10_11_1 doi: 10.1001/jama.2020.8946 – ident: e_1_2_10_20_1 doi: 10.1016/j.lansea.2022.100036 – ident: e_1_2_10_60_1 doi: 10.1371/journal.pone.0021207 – ident: e_1_2_10_5_1 doi: 10.1016/S1473-3099(22)00320-6 – volume: 11 year: 2020 ident: e_1_2_10_80_1 publication-title: Nat. Commun. – ident: e_1_2_10_19_1 doi: 10.1001/jamaoto.2020.3053 – year: 2022 ident: e_1_2_10_26_1 publication-title: Preprint, Research Square – ident: e_1_2_10_7_1 doi: 10.1056/NEJMoa2107058 – ident: e_1_2_10_54_1 doi: 10.1186/s12989-020-0339-8 – ident: e_1_2_10_30_1 doi: 10.1002/lary.29935 – ident: e_1_2_10_24_1 doi: 10.1002/EXP.20210038 – ident: e_1_2_10_75_1 doi: 10.1126/sciimmunol.abl9929 – ident: e_1_2_10_58_1 doi: 10.1007/978-1-4614-7978-9_5 – ident: e_1_2_10_4_1 doi: 10.1001/jamanetworkopen.2022.6108 – ident: e_1_2_10_35_1 doi: 10.1152/ajplung.00552.2020 – ident: e_1_2_10_41_1 doi: 10.1038/s43246-021-00153-y – ident: e_1_2_10_47_1 doi: 10.1016/j.cegh.2021.100826 – ident: e_1_2_10_69_1 doi: 10.4168/aair.2019.11.3.306 – ident: e_1_2_10_70_1 doi: 10.1038/s41586-021-03673-2 – ident: e_1_2_10_34_1 doi: 10.1016/j.carres.2014.02.018 – ident: e_1_2_10_53_1 doi: 10.3389/fbioe.2020.581995 – ident: e_1_2_10_37_1 doi: 10.1021/acs.jpcc.7b03885 – ident: e_1_2_10_1_1 doi: 10.1513/AnnalsATS.201311-405PS – ident: e_1_2_10_33_1 doi: 10.1016/j.xphs.2015.12.016 – ident: e_1_2_10_39_1 doi: 10.1016/j.apm.2022.08.008 – ident: e_1_2_10_68_1 doi: 10.1016/j.ejpb.2007.01.010 – ident: e_1_2_10_43_1 doi: 10.1002/viw2.16 – ident: e_1_2_10_51_1 doi: 10.1016/j.resp.2008.05.018 – ident: e_1_2_10_71_1 doi: 10.1038/ni1001-907 |
SSID | ssj0009606 |
Score | 2.468977 |
Snippet | Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of... Nasal sprays for pre-exposure prophylaxis against respiratory infections show limited protection (20-70%), largely due to their single mechanism of... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e2406348 |
SubjectTerms | Administration, Intranasal Animals antibacterial antiviral Barriers broad spectrum protection Disease Models, Animal Droplets Effectiveness Infections Mice nasal prophylaxis nasal spray Nasal Sprays Neutralizing Orthomyxoviridae Infections - prevention & control pathogen capture Pathogens Prophylaxis respiratory infections Respiratory Tract Infections - prevention & control Respiratory Tract Infections - virology virus neutralization |
Title | Toward a Radically Simple Multi‐Modal Nasal Spray for Preventing Respiratory Infections |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadma.202406348 https://www.ncbi.nlm.nih.gov/pubmed/39318086 https://www.proquest.com/docview/3128450802 https://www.proquest.com/docview/3109421810 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT4QwEJ4YT3rw_cBXamLiCcUWKBw3PqIm62HVRE9kKK0xGta4uwc9-RP8jf4SO2VhXT2Y6IVASqF0Osw37cxXgB3MY6ETpXwVGu2HFiL7Kc-1L_LE8EAhpoamBtoX8el1eH4T3XzJ4q_4IZoJN9IM978mBce8tz8iDcXC8QaRRRIhZftSwBahos6IP4rguSPbE5GfxmFSszYGfH-8-rhV-gE1x5GrMz0ns4B1o6uIk4e9QT_fU6_f-Bz_81VzMDPEpaxVDaR5mNDlAkx_YStchNsrF2LLkHXQre48vrDLe2IXZi6N9-Ptvd0t7EMusGePl0_P-MIsJmY1TVR5xzqjlX12NowDK3tLcH1yfHV46g93ZvCV4Fa1jBBKSoFEJm_9N2l4XkQyNCmqQlqNLw6QK6MwKFSqUMXGhLRHVmR9R23LpFiGybJb6lVgkhuiqMt1EqcWLcikwNBgoLX1o1IVSw92a8lkTxUBR1ZRLfOMOitrOsuDjVpw2VARe5kg-xtRQrEH202xVSFaF8FSdwd0j_VxCeoEHqxUAm9eJVL707Nunwfcie2XNmSto3aruVr7S6V1mKLzKt9xAyb7zwO9aYFPP99yg_sTMOT6wA |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB71caAcoEALabdgpEqcsg12EifHFbDatps97EMqp8hxbIRA2dU-DuXUn9Df2F9Sj_NYthwqlUukxHHieDyZb-yZzwCnIguZiqR0pa-V6xuI7MY0Uy7LIk09KUSscWogGYS9iX9xFdTRhJgLU_JDNBNuqBn2f40KjhPSZ2vWUJFb4iA0ScyPtmEXt_W2XtVwzSCFAN3S7bHAjUM_qnkbPXq2WX_TLv0DNjexqzU-3ZeQ1c0uY05-tVfLrC3_PGB0_K_v2ocXFTQlnXIsvYItVbyG538RFr6B72MbZUsEGQq7wPP7mox-IsEwsZm8dze3yTQ3DxmIhTmOZnNxTQwsJjVTVPGDDNeL--S8CgUrFgcw6X4bf-m51eYMrmTUaJdmTHLOBPLJGxeOa5rlAfd1LGTOjdLnnwWVWgovl7EUMtTax22yAuM-KlPG2SHsFNNCvQPCqUaWukxFYWwAA49y4WvhKWVcqViG3IFPtWjSWcnBkZZsyzTFzkqbznKgVUsurXRxkTI0wQHmFDvwsSk2WoRLI6JQ0xXeY9xcRDueA29LiTevYrH57xnPzwFq5fZIG9LO16TTnB09pdIHeNYbJ_20fz64PIY9vF6mP7ZgZzlfqRODg5bZezvS7wHhxP7b |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BkRAcyj9NKWAkJE5pUzuJk-OKZdUCu0LbViqnaOLYqAJlV93dQznxCH1GnoQZZ5Pt0gNSuURKHMeOx-P5xvZ8BniLZapsZkxoYmfDmCBymMvShqrMnIwMYu54amA4Sg9O4o-nyemVKP6GH6KbcGPN8OM1K_i0cnsr0lCsPG8QWyQVZ7fhDhWUcb_uj1cEUozPPdueSsI8jbOWtjGSe-v5183SNay5Dl297Rk8AGxr3Ww5-b67mJe75udfhI7_81sPYXMJTEWv6UmP4JatH8P9K3SFT-Drsd9jK1CM0S_v_LgQR2dMLyx8HO_vX5fDSUUfGeGMrkfTc7wQBIpFyxNVfxPj1dK-OFxuBKtnT-Fk8OH4_UG4PJohNEqSbjmljNYKmU2eHDjtZFklOnY5mkqTylf7KI0zGFUmN2hS52I-JCsh59FSmlbPYKOe1HYLhJaOOepKm6U5wQWdVRg7jKwlRyo3qQ7gXSuZYtowcBQN17IsuLGKrrEC2GkFVyw1cVYoNsAJRxQH8KZLJh3ihRGs7WTB75CTy1gnCuB5I_CuKJXTqEd-XwDSi-0fdSh6_WGvu9u-SabXcPdLf1B8Phx9egH3-HET-7gDG_PzhX1JIGhevvL9_A_8g_2T |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toward+a+Radically+Simple+Multi%E2%80%90Modal+Nasal+Spray+for+Preventing+Respiratory+Infections&rft.jtitle=Advanced+materials+%28Weinheim%29&rft.au=Joseph%2C+John&rft.au=Helna%2C+Mary+Baby&rft.au=Joselyn+Rojas+Quintero&rft.au=Kenney%2C+Devin&rft.date=2024-11-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0935-9648&rft.eissn=1521-4095&rft.volume=36&rft.issue=46&rft_id=info:doi/10.1002%2Fadma.202406348&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0935-9648&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0935-9648&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0935-9648&client=summon |